UK inflation unexpectedly eases in December, which could reduce pressure in bond markets
Body count from South African mine siege rises to 60
US importers rush in goods from China as Trump tariff threat looms
Novak Djokovic breaks a tie with Roger Federer for the most Grand Slam matches in tennis history
China's RedNote: what you need to know about the app TikTok users are flocking to
British author Neil Gaiman denies ever engaging in non-consensual sex as more accusers come forward
(Reuters) - Amylyx Pharmaceuticals has agreed to buy the rights to bankrupt drugmaker Eiger BioPharmaceuticals' experimental drug for low blood sugar in a $35.1 million deal, Eiger said in a filing on Friday.
Amylyx's acquisition of avexitide would mean a foray into drug development for metabolic diseases. The company had so far been a developer of drugs to treat neurodegenerative diseases.
Avexitide is a GLP-1 antagonist drug that help treat low blood sugar, the opposite of what diabetes and weight-loss medicines such as Novo Nordisk's Ozempic and Wegovy, and Eli Lilly's Mounjaro and Zepbound do.
In April, Amylyx announced its plans to remove Relyvrio - its approved drug for amyotrophic lateral sclerosis (ALS) - from the market after failing in a key late-stage trial.
Amylyx did not immediately respond to Reuters' request for comment.
Eiger has tested avexitide in mid-stage studies as a potential treatment for low blood sugar caused by bariatric surgery and also a metabolic disorder called congenital hyperinsulinism.
Congenital hyperinsulinism occurs in newborns and causes permanent brain damage and life-long insulin-dependent diabetes.
Separately, Eiger had filed for Chapter 11 bankruptcy in April.
(Reporting by Puyaan Singh in Bengaluru; Editing by Alan Barona)
